Further clinical studies to evaluate combinations of hormone therapy with PI3K, AKT, mTOR, or CDK 4/6 inhibitors, together with clinical trials in other breast subtypes, are still ongoing and will lead to improved therapies to treat breast cancer patients. This evidence concerns the gene PIK3CB and breast cancer.